後天性血友病治療の世界市場レポート 2024

後天性血友病治療の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には5.1%の年間複合成長率（CAGR）で148億8,000万米ドルに成長すると予想されます。予測期間中に予想される拡大は、世界人口の増加、ヘルスケア投資の増加、個別化医療の動向、調査における国際協力、ヘルスケア意識の高まり、希少疾病用医薬品に対する規制支援などの要因に起因すると考えられます。予測期間の主な動向には、モニタリングおよび診断技術の進歩、患者支援プログラムでの協力、遺伝子治療アプローチの調査、免疫寛容誘導の利用増加、遠隔診療のための遠隔医療の導入などが含まれます。

後天性血友病治療市場で予想される成長は、進行中の臨床試験の数の増加によって促進されると予想されます。人間の参加者を対象とした調査研究を含む臨床試験は、後天性血友病に対する新しい治療法の安全性と有効性を評価する上で重要な役割を果たします。これらの試験は、調査の進歩、患者の転帰の向上、効果的な治療介入の確立に貢献します。 ClinicalTrials.govによると、2023年 10月の時点で、世界の登録研究数は、米国の50州すべてと221か国で2022年の437,523件から468,457件に増加しました。米国だけで143,613件の研究（全体の31%）を占め、米国以外の地域では251,159件の研究（全体の54%）が登録されました。したがって、進行中の臨床試験の数の増加は、後天性血友病治療市場の重要な推進力となります。

後天性血友病治療市場の成長は、ヘルスケア費の増加によって促進されると予想されます。特定の期間内にヘルスケア製品やサービスに費やされた総額を表すヘルスケア支出は、後天性血友病に対する高度な治療、医療介入、包括的なケアへのアクセスを促進する上で重要な役割を果たします。 2023年3月、米国医師協会は、2021年の米国のヘルスケア支出は4兆3,000億米ドルに達し、一人当たりの支出は1万2,914米ドルに達したと報告しました。医師支出は平均3.8%増加しましたが、病院サービス（4.5%）と臨床サービス（6.6%）の増加率は大きくなっています。したがって、ヘルスケア支出の増加が後天性血友病治療市場を牽引します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の後天性血友病治療市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• オンデマンド
• 予防
• 世界の後天性血友病治療市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 血友病A
• 血友病B
• 血友病C
• その他のタイプ
• 世界の後天性血友病治療市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 診療所
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の後天性血友病治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の後天性血友病治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 後天性血友病治療市場の競合情勢
• 後天性血友病治療市場の企業プロファイル
  • Pfizer Inc.
  • Roche Holding AG
  • Bayer AG
  • Novartis AG
  • Bristol-Myers Squibb Company

第31章 その他の主要および革新的な企業

• Sanofi SA
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Novo Nordisk A/S
• Baxter Healthcare Corporation
• Teva Pharmaceutical Industries Ltd.
• Mylan NV
• Biogen Inc.
• CSL Limited
• Grifols SA
• Genentech Inc.
• Octapharma AG
• Ferring Pharmaceuticals BV
• Shire plc

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

The treatment of acquired hemophilia refers to therapeutic approaches utilized to manage and address this non-hereditary bleeding disorder. It arises from a mutation or alteration in one of the genes responsible for producing clotting factor proteins crucial for blood clot formation. The treatment involves various strategies, including controlling bleeding episodes and eliminating inhibitors that target clotting factors.

The primary treatments for acquired hemophilia include on-demand and prophylaxis. On-demand treatment involves administering clotting factor replacement therapy only in response to clinically significant bleeding. Hospitals, clinics, and other end users prescribe this treatment for hemophilia A, hemophilia B, hemophilia C, and other related conditions.

The acquired hemophilia treatment market research report is one of a series of new reports from The Business Research Company that provides acquired hemophilia treatment market statistics, including acquired hemophilia treatment industry global market size, regional shares, competitors with an acquired hemophilia treatment market share, detailed acquired hemophilia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the acquired hemophilia treatment industry. This acquired hemophilia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The acquired hemophilia treatment market size has grown strongly in recent years. It will grow from $11.47 billion in 2023 to $12.2 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth observed during the historical period can be attributed to factors such as the increasing aging population, improved diagnostics and awareness, expansion of the patient pool, collaborative research initiatives, and regulatory support and approvals.

The acquired hemophilia treatment market size is expected to see strong growth in the next few years. It will grow to $14.88 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. The expansion anticipated in the forecast period can be attributed to factors such as the growing global population, increased healthcare investments, trends in personalized medicine, international collaborations in research, rising healthcare awareness, and regulatory support for orphan drugs. Major trends in the forecast period include advancements in monitoring and diagnostic technologies, collaboration for patient support programs, research on gene therapy approaches, increased utilization of immune tolerance induction, and the adoption of telemedicine for remote consultations.

The anticipated growth in the acquired hemophilia treatment market is expected to be driven by an increasing number of ongoing clinical trials. Clinical trials, which involve research studies with human participants, play a crucial role in evaluating the safety and effectiveness of new medical treatments for acquired hemophilia. These trials contribute to advancing research, enhancing patient outcomes, and establishing effective therapeutic interventions. As of October 2023, according to ClinicalTrials.gov, the number of registered studies globally increased from 437,523 in 2022 to 468,457 across all 50 states in the United States and 221 countries. The U.S. alone accounted for 143,613 studies (31% of the total), while non-U.S. locations registered 251,159 studies (54% of the total). Hence, the growing number of ongoing clinical trials is a significant driver for the acquired hemophilia treatment market.

The growth of the acquired hemophilia treatment market is expected to be fueled by the increasing healthcare expenditure. Healthcare expenditure, representing the total amount spent on healthcare goods and services within a specific period, plays a crucial role in facilitating access to advanced therapies, medical interventions, and comprehensive care for acquired hemophilia. In March 2023, the American Medical Association reported that healthcare spending in the United States reached $4.3 trillion in 2021, with a per capita expenditure of $12,914. Physician spending increased by 3.8% on average, while hospital services (4.5%) and clinical services (6.6%) experienced larger growth rates. Therefore, the rising healthcare expenditure drives the acquired hemophilia treatment market.

The high cost associated with bypassing agents may act as a hindrance to the market's growth during the forecast period. The elevated cost of these agents may limit access to essential treatment for individuals with acquired hemophilia, potentially leading to delayed or suboptimal care and increased risks of severe bleeding episodes. For example, a study by the National Library of Medicine in June 2023 revealed that the average annual healthcare cost for patients ranged from $213,874 to $869,940 in 2021, driven mainly by factors such as Hemophilia A (Factor VIII Deficiency), bypassing agents, and emicizumab. Thus, the high cost of bypassing agents poses a challenge to the growth of the acquired hemophilia treatment market.

Major companies in the acquired hemophilia treatment market are actively focused on obtaining approvals for drugs with additional measures to strengthen their market position. Drug approvals that include routine prophylaxis are increasing, addressing the need for more effective and safer treatment options. For instance, in June 2022, Chugai Pharmaceutical received extended approval from Japan's Ministry of Health, Labor and Welfare to expand the use of Hemlibra (emicizumab) for routine prophylaxis in acquired hemophilia A patients, aiming to reduce or minimize the occurrence of bleeds. This bispecific antibody simultaneously targets factor IX and factor X binding sites, enhancing the control of bleeding in patients.

In June 2023, Baudax Bio. completed the acquisition of TeraImmune Inc., an advanced research company based in the U.S., for an undisclosed amount. This strategic move aimed to combine TeraImmune's scientific expertise with Baudax Bio.'s proficiency in executing clinical development programs. The acquisition incorporated TeraImmune's TI-168 asset, a promising next-generation, autologous FVIII TCR-Treg cell therapy candidate designed to neutralize clotting factor VIII (FVIII) inhibitors in Hemophilia A patients. TeraImmune Inc. contributed valuable advancements in the field of treatments for hemophilia.

Major companies operating in the acquired hemophilia treatment market report are Pfizer Inc., Roche Holding AG, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Baxter Healthcare Corporation, Teva Pharmaceutical Industries Ltd., Mylan NV, Biogen Inc., CSL Limited, Grifols SA, Genentech Inc., Octapharma AG, Ferring Pharmaceuticals BV, Shire PLC, BioMarin Pharmaceutical Inc., Sobi Inc., Kedrion Biopharma Inc., Chugai Pharmaceutical Co. Ltd., Spark Therapeutics Inc., Medexus Pharmaceuticals Inc., UniQure NV, Catalyst Biosciences Inc., Hema Biologics LLC, BioXcel Corporation

North America was the largest region in the acquired hemophilia treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired hemophilia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the acquired hemophilia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acquired hemophilia treatment market consists of revenues earned by entities by providing services such as eradication of inhibitors, individualized therapeutic approach, multidisciplinary approach, and prevention services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acquired hemophilia treatment market also includes sales of immunosuppressive agents including cyclosporine A, and azathioprine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acquired Hemophilia Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acquired hemophilia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acquired hemophilia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acquired hemophilia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Treatment: On-Demand; Prophylaxis
• 2) By Type: Hemophilia A; Hemophilia B; Hemophilia C; Other Types
• 3) By End User: Hospitals; Clinic; Other End Users
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Bayer AG; Novartis AG; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acquired Hemophilia Treatment Market Characteristics

3. Acquired Hemophilia Treatment Market Trends And Strategies

4. Acquired Hemophilia Treatment Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Acquired Hemophilia Treatment Market Size and Growth

• 5.1. Global Acquired Hemophilia Treatment Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Acquired Hemophilia Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Acquired Hemophilia Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Acquired Hemophilia Treatment Market Segmentation

• 6.1. Global Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• On-Demand
• Prophylaxis
• 6.2. Global Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hemophilia A
• Hemophilia B
• Hemophilia C
• Other Types
• 6.3. Global Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Clinic
• Other End Users

7. Acquired Hemophilia Treatment Market Regional And Country Analysis

• 7.1. Global Acquired Hemophilia Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Acquired Hemophilia Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Acquired Hemophilia Treatment Market

• 8.1. Asia-Pacific Acquired Hemophilia Treatment Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Acquired Hemophilia Treatment Market

• 9.1. China Acquired Hemophilia Treatment Market Overview
• 9.2. China Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Acquired Hemophilia Treatment Market

• 10.1. India Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Acquired Hemophilia Treatment Market

• 11.1. Japan Acquired Hemophilia Treatment Market Overview
• 11.2. Japan Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Acquired Hemophilia Treatment Market

• 12.1. Australia Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Acquired Hemophilia Treatment Market

• 13.1. Indonesia Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Acquired Hemophilia Treatment Market

• 14.1. South Korea Acquired Hemophilia Treatment Market Overview
• 14.2. South Korea Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Acquired Hemophilia Treatment Market

• 15.1. Western Europe Acquired Hemophilia Treatment Market Overview
• 15.2. Western Europe Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Acquired Hemophilia Treatment Market

• 16.1. UK Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Acquired Hemophilia Treatment Market

• 17.1. Germany Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Acquired Hemophilia Treatment Market

• 18.1. France Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Acquired Hemophilia Treatment Market

• 19.1. Italy Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Acquired Hemophilia Treatment Market

• 20.1. Spain Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Acquired Hemophilia Treatment Market

• 21.1. Eastern Europe Acquired Hemophilia Treatment Market Overview
• 21.2. Eastern Europe Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Acquired Hemophilia Treatment Market

• 22.1. Russia Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Acquired Hemophilia Treatment Market

• 23.1. North America Acquired Hemophilia Treatment Market Overview
• 23.2. North America Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Acquired Hemophilia Treatment Market

• 24.1. USA Acquired Hemophilia Treatment Market Overview
• 24.2. USA Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Acquired Hemophilia Treatment Market

• 25.1. Canada Acquired Hemophilia Treatment Market Overview
• 25.2. Canada Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Acquired Hemophilia Treatment Market

• 26.1. South America Acquired Hemophilia Treatment Market Overview
• 26.2. South America Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Acquired Hemophilia Treatment Market

• 27.1. Brazil Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Acquired Hemophilia Treatment Market

• 28.1. Middle East Acquired Hemophilia Treatment Market Overview
• 28.2. Middle East Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Acquired Hemophilia Treatment Market

• 29.1. Africa Acquired Hemophilia Treatment Market Overview
• 29.2. Africa Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Acquired Hemophilia Treatment Market Competitive Landscape And Company Profiles

• 30.1. Acquired Hemophilia Treatment Market Competitive Landscape
• 30.2. Acquired Hemophilia Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Roche Holding AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Bayer AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Novartis AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bristol-Myers Squibb Company
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Acquired Hemophilia Treatment Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. GlaxoSmithKline plc
• 31.3. Takeda Pharmaceutical Company Limited
• 31.4. Amgen Inc.
• 31.5. Novo Nordisk A/S
• 31.6. Baxter Healthcare Corporation
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Mylan NV
• 31.9. Biogen Inc.
• 31.10. CSL Limited
• 31.11. Grifols SA
• 31.12. Genentech Inc.
• 31.13. Octapharma AG
• 31.14. Ferring Pharmaceuticals BV
• 31.15. Shire plc

32. Global Acquired Hemophilia Treatment Market Competitive Benchmarking

33. Global Acquired Hemophilia Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Acquired Hemophilia Treatment Market

35. Acquired Hemophilia Treatment Market Future Outlook and Potential Analysis

• 35.1 Acquired Hemophilia Treatment Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Acquired Hemophilia Treatment Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Acquired Hemophilia Treatment Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer